ArticleVirulence2025
Pathogenicity and pathobiological characterization of a recombinant genotype I/II African swine fever virus in pigs.
Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- African swine fever in the era of global expansion: Epidemiology, transmission dynamics, viral evolution, and One Health control strategies.Veterinary world · 2026Review
- Live-Attenuated Vaccines Against African Swine Fever: Strategies, Lessons, and Prospects.Biology · 2026Review
- Experimental comparison of African swine fever virus exposure through contaminated feed and infected pig organ homogenate.Frontiers in veterinary science · 2026Article
- First detection of African swine fever in a swine farm in Taiwan.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is a highly contagious pathogen affecting domestic pigs and wild boar, causing substantial economic losses. Recently, a highly virulent recombinant ASFV strain combining genotypes I and II (rASFV I/II) emerged in Asia. Genotype II ASFV vaccine candidates have failed to effectively protect against rASFV I/II infection, presenting a critical challenge. Here, we investigated the pathobiological characteristics of rASFV I/II in domestic pigs. Ten healthy 7-week-old female pigs were intramuscularly inoculated with an rASFV I/II strain. Clinical signs, rectal temperatures, and samples were collected daily, and necropsies were conducted postmortem. All inoculated pigs succumbed to infection within 5-7 days post-inoculation (dpi), with a mean of 5.5 ± 0.7 dpi. High fever ( > 40.5°C) was observed at an average onset of 2.6 ± 0.8 dpi, and the incubation period averaged 3.0 ± 1.1 dpi. Viral DNA was first detected in blood at 2 dpi, with viral genome copies increasing steadily. Postmortem analysis revealed severe congestive splenomegaly and hemorrhagic lymphadenopathy in all pigs. A preliminary comparison of histopathological lesions in early phase of viral infection showed that all three rASFV I/II-infected pigs showed endothelial injury lesions, while only one genotype II ASFV-infected pig showed this lesion. High viral DNA copy numbers were detected in all organs, particularly the liver, lymph nodes, spleen, lungs, and kidneys. These findings demonstrated distinct pathobiological features of rASFV I/II that warrant further investigation for their implications on disease control. The results also emphasized the urgent need for enhanced surveillance in Asia, rapid diagnostic methods, and effective vaccines targeting emerging ASFV variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.